Drug Profile
Research programme: Candida albicans vaccine - Roche/TheraCarb
Latest Information Update: 05 Aug 2013
Price :
$50
*
At a glance
- Originator TheraCarb
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Candidiasis
Most Recent Events
- 30 Nov 2010 Discontinued - Preclinical for Candidiasis in Canada (unspecified route)
- 30 Nov 2009 No development reported - Preclinical for Candidiasis in Canada (unspecified route)
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche